Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2025-04-21 Management Reports
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：2025年度“提质增效重回报”行动方案
Management Reports Classification · 95% confidence The document is a detailed action plan report from Shanghai Medicilon Biopharmaceutical Co., Ltd. for the year 2025, including a review of the 2024 plan and outlining strategic initiatives for 2025. It covers business development, governance improvements, investor relations, and shareholder return mechanisms such as dividends and share repurchases. The content is comprehensive and forward-looking, focusing on management strategy, operational improvements, governance, and investor communication rather than presenting financial statements or audit results. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement or certification. The document aligns best with a Management Reports (MDA) filing, which includes management's detailed explanation of business trends, strategy, and outlook.
2025-04-21 Chinese
美迪西：关于召开2024年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of Shanghai Medicilon Biopharmaceutical Co., Ltd. It includes information about the meeting date, voting methods, agenda items to be discussed and voted on, shareholder registration details, and instructions for proxy voting. The document does not contain financial statements or detailed financial analysis but rather focuses on the logistics and agenda of the upcoming AGM. It is not an annual report, earnings release, or any other financial report but a formal announcement and notice related to the AGM. Therefore, the document fits the category of AGM Information (AGM-R). The document length (5655 characters) and content confirm it is a full notice rather than a brief announcement or a report publication announcement.
2025-04-21 Chinese
美迪西：第四届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the third meeting of the fourth Supervisory Board of Shanghai Medicilon Inc. It includes multiple agenda items such as approval of the 2024 Supervisory Board Work Report, 2024 Financial Final Report, 2024 Profit Distribution Plan, 2024 Annual Report and its summary, 2025 Employee Stock Ownership Plan draft and management measures, 2024 Fundraising Use Report, Supervisory Board remuneration plan, asset impairment provisions, expected 2025 related party transactions, investment and related party transactions by subsidiaries, and the 2024 ESG report. The document repeatedly states that these reports and plans are published separately on the Shanghai Stock Exchange website and that the resolutions will be submitted to the shareholders' meeting for approval. The document itself does not contain the full annual report or financial statements but is a formal meeting resolution announcement summarizing the supervisory board's approvals and opinions on these reports and plans. The document length is 4081 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement of supervisory board meeting resolutions and references to other reports published elsewhere, rather than the reports themselves.
2025-04-21 Chinese
美迪西：立信会计师事务所（特殊普通合伙）关于公司2024年度非经营性资金占用及其他关联资金往来情况的专项报告
Regulatory Filings
2025-04-21 Chinese
美迪西：2024年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as "2024 年年度报告摘要" which translates to "2024 Annual Report Summary". It contains detailed financial data for the year 2024, including total assets, net profit, revenue, quarterly financial data, shareholder information, business overview, industry analysis, risk factors, and management discussion. The document is comprehensive and includes substantive financial data and analysis for the full fiscal year 2024. It is not a brief announcement or a certification letter but a detailed summary of the annual report. Therefore, it fits the definition of an Annual Report (10-K). FY 2024
2025-04-21 Chinese
美迪西：董事会审计委员会2024年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2024年度履职情况报告" (2024 Annual Performance Report) of the Board Audit Committee of Shanghai Medicilon Inc. It details the audit committee's activities, meetings, supervision of external and internal audits, review of financial reports, and internal control guidance for the year 2023. The content focuses on the audit committee's work and oversight rather than presenting standalone audit opinions or detailed financial statements. The document is a report on the audit committee's performance and activities, which aligns with the category of Audit Report / Information (AR). The document length is 1801 characters, which is short but contains substantive content about audit committee duties and evaluations, not merely an announcement or certification. Therefore, it is classified as AR with high confidence. FY 2024
2025-04-21 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.